53.66

0.41% -0.22

After Hours: 53.73 0.07 +0.13%

Akero Therapeutics Inc (AKRO)

Overview News Price History Option Chain Financials Why AKRO Down? Discussions Forecast

Akero Therapeutics Inc stock is traded at $53.66, with a volume of 5.35M. It is down -0.41% in the last 24 hours and up +23.47% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Previous Close:

$53.88

Open:

$53.95

24h Volume:

5.35M

Relative Volume:

2.95

Market Cap:

$4.29B

Revenue:

Net Income/Loss:

$-269.44M

P/E Ratio:

-14.31

EPS:

-3.75

Net Cash Flow:

$-262.63M

1W Performance:

+16.55%

1M Performance:

+23.47%

6M Performance:

+50.46%

1Y Performance:

+81.10%

1-Day Range:

$53.65

$54.08

1-Week Range:

$45.50

$54.53

52-Week Range:

$21.34

$58.40

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name

Akero Therapeutics Inc

Sector

Healthcare (1142)

Industry

Biotechnology (639)

Phone

650-487-6488

Address

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Employee

Twitter

@akerotx

Next Earnings Date

2025-08-08

Latest SEC Filings

AKRO's Discussions on Twitter

Compare AKRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKRO Akero Therapeutics Inc	53.66	4.32B	0	-269.44M	-262.63M	-3.75
VRTX Vertex Pharmaceuticals Inc	407.37	104.55B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	464.95	60.36B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	557.73	59.84B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	799.56	49.07B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	327.03	35.16B	4.56B	-176.77M	225.30M	-1.7177

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-04-25	Resumed	H.C. Wainwright	Buy
Aug-04-25	Initiated	TD Cowen	Buy
Jan-30-25	Upgrade	BofA Securities	Neutral → Buy
Jan-27-25	Reiterated	H.C. Wainwright	Buy
Nov-18-24	Initiated	Citigroup	Buy
Apr-22-24	Resumed	BofA Securities	Neutral
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight
Aug-28-23	Initiated	UBS	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-10-21	Initiated	BofA Securities	Buy
Feb-26-21	Initiated	Guggenheim	Buy
Sep-10-20	Initiated	Morgan Stanley	Overweight
Jul-20-20	Reiterated	H.C. Wainwright	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy
Jul-01-20	Reiterated	H.C. Wainwright	Buy
Mar-02-20	Initiated	H.C. Wainwright	Buy
Feb-10-20	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Evercore ISI	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight
Jul-15-19	Initiated	Jefferies	Buy
Jul-15-19	Initiated	ROTH Capital	Buy

View All

Akero Therapeutics Inc Stock (AKRO) Latest News

11:41 AM

Will Akero Therapeutics Inc. stock reach Wall Street targetsMarket Growth Summary & AI Optimized Trade Strategies - newser.com

11:41 AM

10:42 AM

Novo Nordisk to Acquire Akero Therapeutics for $4.7B - Contract Pharma

10:42 AM

09:50 AM

Is Akero Therapeutics Inc. forming a bottoming baseJuly 2025 Closing Moves & High Yield Stock Recommendations - newser.com

09:50 AM

09:27 AM

Is Akero Therapeutics Inc. stock bottoming outWeekly Investment Report & Verified Stock Trade Ideas - newser.com

09:27 AM

08:03 AM

TD Cowen Downgrades Akero Therapeutics to Hold From Buy, Adjusts Price Target to $58 From $76 - MarketScreener

08:03 AM

05:54 AM